Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D05FWH
|
|||
Former ID |
DNCL002660
|
|||
Drug Name |
SCH-900776
|
|||
Synonyms |
CHEMBL1643208; MK-8776; 6-bromo-3-(1-methyl-1H-pyrazol-4-yl)-5-(piperidin-3-yl)pyrazolo[1,5-a]pyrimidin-7-amine; GTPL7943; SCHEMBL10380123; CHEBI:131165; HMS3656J19; BCP02883; BDBM50334854; AKOS026750519; MK 8776; NCGC00387868-02; DA-40779; 4CA-1150; BCP0726000317; J3.517.083I; 891494-63-6 pound not SCH900776 pound not SCH-900776; 6-bromo-3-(1-methylpyrazol-4-yl)-5-piperidin-3-ylpyrazolo[5,1-b]pyrimidin-7-amine; 6-bromo-3-(1-methylpyrazol-4-yl)-5-[(3S)-piperidin-3-yl]pyrazolo[1,5-a]pyrimidin-7-amine
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 2 | [1], [2] | |
Company |
Merck
|
|||
Structure |
Download2D MOL |
|||
Formula |
C15H18BrN7
|
|||
Canonical SMILES |
CN1C=C(C=N1)C2=C3N=C(C(=C(N3N=C2)N)Br)C4CCCNC4
|
|||
InChI |
1S/C15H18BrN7/c1-22-8-10(6-19-22)11-7-20-23-14(17)12(16)13(21-15(11)23)9-3-2-4-18-5-9/h6-9,18H,2-5,17H2,1H3/t9-/m1/s1
|
|||
InChIKey |
GMIZZEXBPRLVIV-SECBINFHSA-N
|
|||
CAS Number |
CAS 891494-63-6
|
|||
PubChem Compound ID | ||||
PubChem Substance ID |
References | Top | |||
---|---|---|---|---|
REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7943). | |||
REF 2 | ClinicalTrials.gov (NCT01870596) Cytarabine With or Without SCH 900776 in Treating Adult Patients With Relapsed Acute Myeloid Leukemia. U.S. National Institutes of Health. | |||
REF 3 | Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening. Mol Cancer Ther. 2011 Apr;10(4):591-602. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.